Raymond James & Associates Grows Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Raymond James & Associates raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 4.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 370,049 shares of the life sciences company's stock after acquiring an additional 16,831 shares during the quarter. Raymond James & Associates owned approximately 0.23% of Illumina worth $50,815,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Trivant Custom Portfolio Group LLC boosted its position in shares of Illumina by 166.7% during the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company's stock worth $27,000 after acquiring an additional 125 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Illumina during the 3rd quarter valued at about $30,000. VisionPoint Advisory Group LLC grew its position in shares of Illumina by 344.6% during the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company's stock valued at $34,000 after purchasing an additional 193 shares in the last quarter. Wetzel Investment Advisors Inc. bought a new stake in shares of Illumina in the fourth quarter worth about $37,000. Finally, Massmutual Trust Co. FSB ADV lifted its position in shares of Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company's stock worth $39,000 after buying an additional 132 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several research analyst reports. Barclays raised their price target on Illumina from $85.00 to $100.00 and gave the company an "underweight" rating in a report on Wednesday, April 10th. StockNews.com lowered shares of Illumina from a "buy" rating to a "hold" rating in a report on Friday. OTR Global reiterated a "mixed" rating on shares of Illumina in a research report on Wednesday, March 20th. Stephens restated an "overweight" rating and issued a $170.00 target price on shares of Illumina in a report on Wednesday, April 10th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $253.00 price target on shares of Illumina in a report on Tuesday, April 9th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $165.10.

Illumina Trading Down 4.9 %

Illumina stock traded down $6.06 during trading hours on Friday, hitting $117.93. The company had a trading volume of 2,987,105 shares, compared to its average volume of 1,375,095. The firm has a market cap of $18.78 billion, a P/E ratio of -14.47 and a beta of 1.20. The company has a 50-day moving average price of $130.03 and a two-hundred day moving average price of $127.02. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $213.91. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.05. The company had revenue of $1.08 billion for the quarter, compared to analysts' expectations of $1.05 billion. Illumina had a positive return on equity of 2.28% and a negative net margin of 28.71%. Illumina's revenue was down 1.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.08 earnings per share. On average, sell-side analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current year.

Insider Activity

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of the stock in a transaction dated Thursday, February 22nd. The stock was purchased at an average price of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares of the company's stock, valued at $2,010,544.69. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.17% of the company's stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.